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Abstract
AIM: To assess the clinical significance and the prog-
nostic value of preoperative serum carbohydrate anti-
gen 19-9 (CA 19-9) level in gastric cancer.
METHODS: Between January 2005 and December 
2006, 1960 patients underwent surgery for histological-
ly confirmed gastric cancer. Of these, 163 patients had 
elevated serum levels of CA 19-9 preoperatively, and 
1628 patients had normal serum levels of CA 19-9 pre-
operatively. For this study, 325 patients were selected 
from the group of 1628 patients by age, sex, and can-
cer stage to serve as controls. Statistically significant 
differences in survival rates were calculated using the 
log-rank test. A P  value less than 0.05 was considered 
statistically significant and was determined using SAS 
software.
RESULTS: The baseline characteristics showed some 
differences between the two groups with regard to his-
tology. Overall survival (OS) in the elevated and non-
elevated group was 37.90 and 68.67 mo, respectively 
(P  < 0.001). N stage (P  = 0.001) was a significant 
predictor of disease-free survival by multivariate analy-
sis. Also, N stage (P  < 0.001), and the presence of 
peritoneal metastasis (P  < 0.001) remained indepen-
dent factors in predicting OS by multivariate analysis. 
Additionally, preoperative serum CA 19-9 levels were 
significantly associated with OS in univariate (P  = 0.009) 
and multivariate (P  = 0.021) analyses. 
CONCLUSION: Serum CA 19-9 can be considered an 
independent prognostic factor in predicting OS in pa-
tients anticipating surgery for gastric cancer.
© 2013 Baishideng. All rights reserved.
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Core tip: The exact functions of preoperative carbo-
hydrate antigen (CA) 19-9 in stomach cancer have 
yet to be uncovered. We sought to assess the clinical 
significance of preoperatively high levels of CA 19-9 in 
patients with gastric cancer and aimed to investigate 
the relationship between serum levels of CA 19-9 and 
disease-free survival and overall survival (OS). We con-
clude that OS in gastric cancer patients with elevated 
CA 19-9 levels was lower than that in patients with 
non-elevated levels. Serum CA 19-9 can be considered 
an independent prognostic factor in predicting OS in 
patients anticipating surgery for gastric cancer.
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INTRODUCTION
Gastric cancer is one of  the most common malignancies 
and the cause of  many cancer-related deaths worldwide. 
Although a single tumor marker is limited for the diag-
nosis of  cancer, it can be used in various clinical aspects, 
including assessment of  clinical status, monitoring of  
treatment response, prediction of  prognoses, and as a 
surveillance marker for recurrence[1-6]. Carcinoembryonic 
antigen (CEA) and carbohydrate antigen (CA) 19-9 are 
tumor markers that are commonly used for the early di-
agnosis and prognostic evaluation of  gastric cancer[7-9], 
potentially reflecting tumor biology[10]. Additionally, the 
relatively new marker cancer antigen, CA 72-4 provides 
prognostic information in gastric cancer[11,12].
Recent clinical studies have shown that CEA and CA 
19-9 are recognized as poor prognostic factors for gas-
tric cancer[13-15] and are related to its recurrence[6,14]. The 
prognostic relevance of  such tumor markers in patients 
with gastric cancer is not comparable with those markers 
used in other carcinomas[5,16-18]. Specifically, CA 19-9 has 
been reported to be elevated in certain forms of  gastric 
cancer[11,19,20]. However, because little research on the 
prognoses of  gastric cancer patients with elevated pre-
operative CA 19-9 levels has been performed, the clinical 
significance of  preoperative CA 19-9 levels has not been 
fully verified[5,13].
Therefore, it is important to interpret the prognostic 
value of  CA 19-9 levels in patients with gastric cancer, 
especially in patients anticipating surgery for postopera-
tive survival. Thus, we sought to assess the clinical signifi-
cance of  preoperatively high levels of  CA 19-9 in patients 
with gastric cancer and aimed to investigate the relation-
ship between serum levels of  CA 19-9 and disease-free 
survival (DFS) and overall survival (OS).
MATERIALS AND METHODS
Patients 
Between January 2005 and December 2006, 1960 patients 
underwent surgery for histologically confirmed gastric 
cancer at Severance Hospital, Seoul, South Korea. Sixty-
nine patients who did not have preoperative serum CA 
19-9 were excluded. Of  the remaining 1891, 163 patients 
had elevated serum levels of  CA 19-9 preoperatively, 
and 1628 patients had normal serum levels of  CA 19-9 
preoperatively. For this study, 325 patients were selected 
from the group of  1628 patients by age, sex, and cancer 
stage to serve as controls. A separate group of  488 pa-
tients who received surgery as a treatment modality for 
confirmed gastric cancer was included and analyzed ret-
rospectively in this study. 
Classification of gastric cancers
The endoscopic findings of  early gastric cancer were clas-
sified according to the criteria of  the Japanese Research 
Society for Gastric Cancer (JRSGC) as follows: elevated 
(types Ⅰ or ⅡA), flat (type ⅡB), depressed (types ⅡC, 
ⅡC + Ⅲ, or ⅡA + ⅡC), and mixed. Advanced gastric 
cancers were categorized according to Borrmann’s classi-
fication. Histological evaluation was performed according 
to the Japanese General Rules for Gastric Cancer Study 
in Surgery and Pathology from the JRSGC[21]. 
In addition, patients were classified into three groups, 
which were based on the location of  the primary lesion: 
upper third, middle third, and lower third. The upper 
third-designated cancer developed in the gastric cardia 
and fundus, the middle third-designated cancer developed 
in the gastric body, and the lower third-designated cancer 
was found in the antrum and pylorus[22].
Treatment modalities
Surgical treatments were considered curative and pal-
liative according to the Union for International Cancer 
Control criteria[23]. The standard surgical treatment was 
radical total or subtotal gastrectomy with D2 lymph node 
dissection in accordance with JRSGC rules[21]. Curative 
resection (R0) was defined as the absence of  tumor ei-
ther macroscopically or microscopically after surgery. In 
selected inoperable cases, palliative gastrectomy was per-
formed when necessary.
Initial work-up and follow-up
A follow up period was started on January 1st, 2005 and 
ended on August 22th, 2008. Initial evaluation included 
complete medical history and physical examination, pay-
ing special attention to symptoms often associated with 
stomach cancer. Chest radiography and laboratory tests 
were performed, including complete blood cell count, 
blood urea nitrogen and creatinine levels, and liver func-
tion tests. Serum CA 19-9 concentrations were measured 
using a commercial chemiluminescent enzyme immuno-
assay with a normal upper limit of  37 U/mL[24]. Serum 
CA 19-9 levels were routinely measured immediately 
before surgery. The entire study population underwent 
esophagogastroduodenoscopy and computed tomog-
raphy of  the abdomen. After surgery, esophagogastro-
duodenoscopy, computed tomography of  the abdomen 
and laboratory tests performed during the initial work-up 
were repeated at each follow-up visit.
Statistical analysis
This study was based on matched pair data considering 
age, sex and cancer stage. In the mixed model, compari-
sons between patients with elevated CA 19-9 levels and 
those with normal levels based on age, sex, cancer stage, 
and survival were performed. Categorical data were eval-
uated by the χ 2 test or Fisher’s exact test, and all continu-
ous variables were expressed as the median (range) and 
analyzed using the Mann-Whitney U test. Multivariate 
analysis of  survival was performed using the Cox pro-
portional hazards model. OS was defined from the date 
of  surgery until death or the date of  last follow-up. DFS 
was defined as the interval from the operation date to the 
date of  confirming recurrence, death from any cause oth-
er than cancer, or last visiting date. Paired Kaplan-Meier 
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Table 1  Baseline characteristics with a comparison of patients 
with elevated serum carbohydrate antigen 19-9 levels and 
normal serum carbohydrate antigen 19-9 levels
curves and Cox regression analyses using robust standard 
error for survival analysis were performed. Statistically 
significant differences in survival rates were calculated 
using the log-rank test. A P value less than 0.05 was con-
sidered statistically significant and was determined using 
SAS software (version 9.1.3, SAS Institute Inc., Cary, NC, 
United States).
RESULTS
Patient characteristics
We compared the outcomes and clinicopathologic char-
acteristics of  163 patients with elevated preoperative 
serum CA 19-9 levels (elevated group) with those of  325 
patients with non-elevated preoperative serum CA 19-9 
levels (non-elevated group), which are summarized in 
Table 1. Baseline characteristics did not show a significant 
statistical relationship between the two groups except 
for histology and serum CA 19-9 levels, which revealed 
a significantly higher proportion of  less differentiated 
adenocarcinoma in patients with elevated preoperative 
serum CA 19-9 levels and mean serum CA 19-9 values 
of  575.74 ± 518.09 U/mL in the elevated group and 8.45 
± 8.42 U/mL in the non-elevated group. However, there 
were no significant differences in baseline characteristics 
with regard to other variables, such as sex, age, endo-
scopic findings, and other serum tumor markers. In 56 
patients, surgery was performed as a palliative treatment. 
Of  these, gastrojejunostomy was performed for bypass 
in 27 patients. Hepatic and peritoneal metastases were ap-
praised by radiological findings, histological examination, 
and/or intraoperative observation. 
Survival outcome according to preoperative CA 19-9 
levels
The median OS was 58.433 mo (95%CI: 43.07-70.90). A 
significantly longer median OS was observed in the non-
elevated group than in the elevated group (68.67 mo vs 
37.90 mo, 95%CI: 25.07-56.13; P < 0.001; Figure 1A). 
Because the majority of  patients died near the end of  the 
study, the upper limit of  the confidence interval in the 
non-elevated group was not calculated. 
As survival curves for DFS did not reach 50% after 
Kaplan-Meier analysis, a median DFS was not defined. A 
longer DFS was seen in the non-elevated group than in 
the elevated group, but the difference was not statistically 
significant (P = 0.099; Figure 1B). 
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Characteristic Elevated group 
 (n  = 163)
Non-elevated group 
 (n  = 325 )
P  value
Sex 0.963
   Male 111 (68.1) 222 (68.3)
   Female   52 (31.9) 103 (31.7)
Mean age, yr 
(range)
60.70 ± 12.00 (29-84) 59.71 ± 12.40 (27-85) 0.295
Number of lesions 0.436
   Single 145 (89.0) 281 (86.5)
   Multiple   18 (11.0)   44 (13.5)
Size (cm)
   Horizontal 6.38 ± 3.51 5.78 ± 3.16 0.060
   Vertical 5.15 ± 2.79 4.66 ± 2.60 0.053
Endoscopic findings 0.135
   EGC
   Elevated 10 (6.1) 23 (7.1)
   Flat   3 (1.8) 15 (1.6)
   Depressed 10 (6.1) 18 (5.5)
AGC
   Borrmann Ⅰ   9 (5.5)   8 (2.5)
   Borrmann Ⅱ   25 (15.3)   38 (11.7) 
   Borrmann Ⅲ   89 (54.6) 203 (62.5)
   Borrmann Ⅳ   17 (10.4) 20 (6.2)
Histology 0.033
   Well 
differentiated
  19 (11.7) 23 (7.1)
   Moderately 
differentiated
  57 (35.0)   86 (26.5)
   Poorly 
differentiated
  54 (33.1) 145 (44.6)
   Signet ring cell 
cancer
  33 (20.3)   71 (21.9)
Location 0.404
   Lower 108 (66.3) 210 (61.6)
   Middle 16 (9.8)   49 (15.1)
   Upper   31 (19.0)   52 (16.0)
   Diffuse   8 (1.9) 14 (4.3)
T stage 0.843
   T0-2   55 (36.7) 117 (37.6)
   T3, 4   95 (63.3) 194 (62.4)
N stage 0.908
   N0, 1   79 (52.7) 162 (52.1)
   N2, 3   71 (47.3) 149 (47.9)
Mean metastatic 0.893
Lymph nodes (N) 9.88 ± 13.03 10.09 ± 11.94
TNM stage > 0.999
   0   1 (0.6)   2 (0.6)
   Ⅰ   26 (16.0)   52 (16.0)
   Ⅱ   21 (12.9)   42 (12.9)
   Ⅲ   57 (35.0) 114 (35.1)
   Ⅳ   58 (35.6) 115 (35.4)
Operation 0.114
   For radical 139 (85.3) 293 (90.2)
   For palliative   24 (14.7) 32 (0.8)
Lymphovascular invasion 0.225
   Positive   98 (76.0) 190 (70.1)
   Negative   31 (24.0)   81 (29.9)
Peritoneal metastasis 0.899
   Positive 10 (6.1) 19 (5.8)
   Negative 153 (93.9) 306 (94.2)
Hepatic metastasis 0.853
   Positive   5 (3.1) 11 (3.4)
   Negative 158 (96.9) 314 (96.6)
Neoadjuvant chemotherapy 0.217
   Positive   6 (3.7)   6 (1.8)
   Negative 157 (96.3) 319 (98.2)
Mean serum CA 
19-9 (range)
575.74 ± 518.09 
(37.4-12800)
8.45 ± 8.42 (0-36.8) < 0.001
Mean serum CEA 
(range)
6.00 ± 21.86 
(0.01-260.27)
5.49 ± 17.30 
(0.01-189.21)
0.777
Mean serum CA 
72-4 (range)
9.31 ± 20.52 
(0.33-164)
14.42 ± 68.61 
(0.2-600)
0.376
Data are expressed as mean ± SD or n (%). AGC: Advanced gastric cancer; 
CA: Carbohydrate antigen; CEA: Carcinoembryonic antigen; EGC: Early 
gastric cancer; TNM: Tumor-node-metastasis. 
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Focusing on OS, univariate analysis demonstrated an as-
sociation with T stage (P < 0.001), N stage (P < 0.001), 
differentiation (P < 0.001), the presence of  lymphovas-
cular invasion (P < 0.001), the presence of  peritoneal 
metastasis (P < 0.001), and hepatic metastasis (P = 0.005). 
Multivariate analysis showed that N stage (P < 0.001), 
and the presence of  peritoneal metastasis (P < 0.001) re-
mained independent factors in predicting OS. Addition-
ally, preoperative serum CA 19-9 levels were significantly 
associated with OS in univariate (P = 0.009) and multi-
variate (P = 0.021) analyses. Cox proportional hazards 
regression analysis indicated that patients with elevated 
levels of  CA 19-9 had a 1.4-fold higher risk of  worse OS 
Prognostic factors
Potential prognostic variables for DFS are presented in 
Table 2. In univariate analysis, DFS was significantly as-
sociated with T stage (P = 0.001), N stage (P < 0.001), 
and the presence of  lymphovascular invasion (P = 0.002). 
Other factors, including age, sex, number of  lesions, dif-
ferentiation, histology, peritoneal metastasis, and hepatic 
metastasis, were not significantly associated with DFS. 
Only N stage (P = 0.001) remained significantly linked 
with DFS in multivariate analysis. Neither univariate nor 
multivariate analyses revealed that preoperative serum CA 
19-9 levels affected DFS.
Potential prognostic variables are shown in Table 2. 
Figure 1  Kaplan-Meier curves. A: Overall survival, P-value by log-rank test < 0.001; B: Disease free survival in patients with elevated serum carbohydrate antigen 
19-9 (CA 19-9) levels (n = 163) and those with normal serum CA 19-9 levels (n = 325), P-value by log-rank test = 0.099. 
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Table 2  Univariate and multivariate analysis of factors associated with disease-free survival
Variable Univariate analysis Multivariate analysis
Hazard ratio (95%CI) P  value Hazard ratio (95%CI) P  value
Disease-free survival
   Age (< 60 vs ≥ 60 yr) 0.737 (0.475-1.143)    0.737 0.620 (0.379-1.015)    0.053
   Sex (male vs female ) 1.140 (0.720-1.806)    0.575 0.777 (0.454-1.331)    0.359
   Lesions (single vs multiple) 1.350 (0.746-2.446)    0.322 0.930 (0.458-1.892)    0.842
   T staging (T 0-2 vs T 3, 4) 2.469 (1.442-4.228)    0.001 1.841 (0.961-3.527)    0.066
   N staging (N 0, 1 vs N 2, 3) 4.069 (2.445-6.772) < 0.001 2.993 (1.587-5.646)    0.001
   Differentiation (well vs poorly) 1.378 (0.863-2.201)    0.179 1.419 (0.786-2.563)    0.246
   Histology (adenocarcinoma vs signet ring cell cancer) 0.979 (0.573-1.674)    0.940 0.599 (0.315-1.142)    0.119
   Lymphovascular invasion (negative vs positive ) 3.054 (1.514-6.161)    0.002   1.15 (0.495-2.674)    0.745
   Peritoneal metastasis (negative vs positive ) 0.956 (0.301-3.034)    0.939 0.507 (0.069-3.704)    0.503
   Hepatic metastasis (negative vs positive )   0.048 (0.000-29.505)    0.354 0.000 (0.000-1.254)    0.962
   CA19-9 (< 37.0 U/mL vs ≥ 37.0 U/mL) 1.385 (0.883-2.172)    0.156 1.179 (0.710-1.958)    0.525
Overall survival
   Age (< 60 vs ≥ 60 yr) 1.047 (0.816-1.342)    0.719 1.218 (0.905-1.639)    0.193
   Sex (male vs female ) 0.979 (0.755-1.269)    0.874 0.995 (0.732-1.355)    0.977
   Lesions (single vs multiple) 1.144 (0.804-1.626)    0.455 1.163 (0.769-1.761)    0.474
   T staging (T 0-2 vs T 3, 4) 2.498 (1.846-3.382) < 0.001 1.437 (0.986-2.094)    0.059
   N staging (N 0, 1 vs N 2, 3) 3.577 (2.713-4.715) < 0.001 2.817 (1.984-4.001) < 0.001
   Differentiation (well vs poorly) 1.595 (1.227-2.073) < 0.001 1.408 (0.990-2.002)    0.057
   Histology (adenocarcinoma vs signet ring cell cancer) 1.171 (0.880-1.560)    0.279 1.000 (0.702-1.424)    0.999
   Lymphovascular invasion (negative vs positive ) 2.527 (1.739-3.673) < 0.001 1.004 (0.643-1.569)    0.985
   Peritoneal metastasis (negative vs positive )   4.620 (3.098-6.6887) < 0.001 3.213 (1.792-5.762) < 0.001
   Hepatic metastasis (negative vs positive ) 2.294 (1.285-4.097)    0.005 2.114 (0.916-4.880)    0.079
   CA19-9 (< 37.0 U/mL vs ≥ 37.0 U/mL) 1.395 (1.087-1.791)    0.009 1.414 (1.053-1.898)    0.021
CA: Carbohydrate antigen. 
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Elevated group
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than patients with low levels of  this marker.
DISCUSSION
Gastric cancer is one of  the most common cancers 
worldwide with approximately 989600 new cases and 
738000 deaths per year, accounting for approximately 8% 
of  new cancers[25]. Thus, gastric cancer continues to be a 
global health problem. However, gastric cancer-specific 
tumor markers have not yet been identified. The tumor 
markers currently in use have limited clinical utility due to 
insufficient specificity and poor sensitivity[14,26,27].
Nevertheless, current serum tumor markers are pri-
marily used for the preoperative staging of  neoplasms, 
postoperative monitoring of  treatment effectiveness, and 
early diagnosis of  recurrence, as they can be easily and 
cost-effectively identified[28]. Specifically, tumor markers, 
including alpha-fetoprotein (AFP), CEA, CA 19-9, CA 
50, and CA 72-4, have been reported to be elevated in 
certain gastric cancer patients[11,19,20]. AFP, a marker com-
monly used for germ cell and hepatocellular carcinoma, is 
elevated in AFP-producing gastric cancer, often present-
ing as liver metastasis and leading to a poor prognosis. 
However, the value of  these tumor markers in gastric 
cancer is still controversial[29-31]. In the case of  CEA, pre-
operative serum CEA levels have been reported to be 
useful for determining or predicting gastric cancer prog-
nosis[11,32,33]. However, some authors have indicated that 
CEA positivity is not a prognostic factor in gastric can-
cer[15]. In addition, earlier studies have reported that CA 
72-4 is more relevant than other tumor markers for gas-
tric cancer, but this has not been verified[13,33-36]. Of  cur-
rently used markers, CA 19-9 is known to have a positive 
correlation with depth of  invasion, nodal involvement, 
and peritoneal metastasis in gastric cancer[15,17,37]. Howev-
er, CA 19-9 can be elevated in endometrial, lung, breast, 
and pancreatic cancers as well as benign conditions, in-
cluding cholecystitis, cholangitis, acute pancreatitis, and 
liver cirrhosis[38,39]. An association between CA 19-9 levels 
and prognosis has not yet been established and remains 
controversial[5,13]. Thus, none of  these markers are used 
alone to diagnose, monitor disease, or predict prognosis. 
Although prognosis is mainly determined by tumor stage 
at the time of  gastric cancer surgery, recent studies have 
assessed the usefulness of  preoperative tumor marker 
levels to predict invasiveness and prognosis[5,6,18,32,33,40].
Therefore, we focused on the prognostic significance 
of  high preoperative levels of  CA 19-9 in patients with 
gastric cancer. The results of  our study indicate that 
measurements of  preoperative serum CA 19-9 levels may 
be useful in the prediction of  survival and prognoses in 
patients with gastric cancer, confirming its association 
with OS and DFS. OS is thought to be influenced by pre-
operative CA 19-9 levels.
Previous studies identified the usefulness of  postoper-
ative CA 19-9 levels to predict prognosis and recurrence 
of  gastric cancer after gastrectomy[6,37]. In many studies, 
however, preoperative CA 19-9 levels were neither prog-
nostic nor were associated with survival. According to 
studies by Dilege et al[17] and Ishigami et al[41], preoperative 
CA 19-9 levels were only significantly correlated with 
lymph node metastasis; patient survival did not correlate 
with preoperative CA 19-9 levels. In addition, Ucar et al[15] 
showed that CA 19-9 was only significantly related to 
lymph node metastasis and peritoneal carcinomatosis, but 
prognosis and survival were not relevant. These authors 
suggested that CA 72-4 was an independent prognostic 
factor for risk of  death in this study. 
These studies did not provide any predictive infor-
mation for preoperative CA 19-9 levels on prognosis or 
survival in gastric cancer patients. One study showed by 
univariate analysis that preoperative CA 19-9 levels could 
predict specific clinical outcomes such as DFS. Another 
study showed poor OS in CA 19-9-positive patients by 
the log-rank test[5]. However, the independent prognostic 
value of  CA 19-9 on OS by Cox regression multivariate 
analysis was not shown[5]. The association between CA 
19-9 levels and stage of  disease, lymph node metasta-
sis, and depth of  invasion has been reported, but none 
have been assigned an independent prognostic value by 
multivariate analysis[5,16,41]. In contrast, our study showed 
survival outcome according to preoperative CA 19-9 lev-
els and prognostic factors for OS and DFS. There were 
significant differences regarding OS between the non-
elevated group and the elevated group. Preoperative CA 
19-9 levels were a reliable prognostic factor for OS in our 
study. With respect to DFS, despite an insignificant prog-
nostic value for CA 19-9 levels, we can see possibilities 
for future research, as our findings are confined to the 
limited data presented here. 
A recent study by Jo et al[42] showed that an elevated 
CA 19-9 concentration before chemotherapy was sig-
nificantly associated with shorter survival especially in 
metastatic or recurrent gastric cancer. The patients in this 
study had metastatic or recurrent gastric cancer. How-
ever, our study was designed to analyze treatment-naïve 
patients who were planning to undergo gastrectomy. 
Therefore, we have superiority and originality compared 
to previous studies due to the differences in the subject 
and focus of  study.
We aimed to determine whether the preoperative tu-
mor marker CA 19-9 could provide useful information 
on clinical outcome and postoperative prognosis similar 
to other common prognostic factors. Unlike the study 
by Marrelli et al[14], we analyzed not only 432 R0 resection 
cases, but also 56 palliative gastrectomy cases; of  these, 
27 cases of  bypass surgery were also included. We cannot 
exclude the possibility that survival rates will appear low 
due to inclusion of  the latter cases and influence tumor 
progression. These factors might affect the tumor burden 
and predominance of  advanced cancer among marker-
positive patients[18]. 
Our study has limitations associated with its retro-
spective nature, single-center design and relatively small 
sample numbers. In addition, preoperative CA 19-9 sam-
pling was not performed at the same time before surgery 
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due to the retrospective design. 
Also, analyses regarding the presence of  chemothera-
py or radiation therapy after surgery were not performed 
in this study. Twelve patients who had neoadjuvant che-
motherapy were included in this study. However, for pa-
tients who had adjuvant chemotherapy or other therapies 
after surgery, analyses were not performed. Although nei-
ther adjuvant nor neoadjuvant chemotherapy showed any 
clear significant survival benefit in gastric cancer[18], these 
factors might be crucial in influencing survival, therefore 
further study is necessary. In the future, it would be inter-
esting to measure CA 19-9 consistently during the preop-
erative examination before surgery and analyze the effects 
of  additional therapies such as adjuvant chemotherapy or 
radiation therapy. Therefore, multi-center and prospec-
tive studies should be designed to certify the prognostic 
significance of  CA 19-9. 
We conclude that OS in gastric cancer patients with 
elevated CA 19-9 levels was lower than that in patients 
with non-elevated levels. Serum CA 19-9 can be consid-
ered an independent prognostic factor in predicting OS 
in patients anticipating surgery for gastric cancer.
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